Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance.

Huang PA, Price DK, Figg WD.

Cancer Biol Ther. 2018;19(10):869-870. doi: 10.1080/15384047.2018.1449618. Epub 2018 May 14.

PMID:
29757697
2.

Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis.

Green DJ, Duong SQ, Burckart GJ, Sissung T, Price DK, Figg WD Jr, Brooks MM, Chinnock R, Canter C, Addonizio L, Bernstein D, Naftel DC, Zeevi A, Kirklin JK, Webber SA, Feingold B.

J Pediatr Pharmacol Ther. 2018 Mar-Apr;23(2):106-110. doi: 10.5863/1551-6776-23.2.106.

3.

Mapping Genomic Scaffolds to Chromosomes Using Laser Capture Microdissection in Application to Hawaiian Picture-Winged Drosophila.

Kang L, George P, Price DK, Sharakhov I, Michalak P.

Cytogenet Genome Res. 2017;152(4):204-212. doi: 10.1159/000481790. Epub 2017 Nov 8.

4.

A Test for Gene Flow among Sympatric and Allopatric Hawaiian Picture-Winged Drosophila.

Kang L, Garner HR, Price DK, Michalak P.

J Mol Evol. 2017 Jun;84(5-6):259-266. doi: 10.1007/s00239-017-9795-7. Epub 2017 May 10.

PMID:
28492967
5.

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP.

J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2.

6.

Incipient ecological speciation between successional varieties of a dominant tree involves intrinsic postzygotic isolating barriers.

Stacy EA, Paritosh B, Johnson MA, Price DK.

Ecol Evol. 2017 Mar 14;7(8):2501-2512. doi: 10.1002/ece3.2867. eCollection 2017 Apr.

7.

Efficacy of androgen deprivation therapy and the role of oxidative stress.

Price DK.

Ann Oncol. 2017 Mar 1;28(3):451-453. doi: 10.1093/annonc/mdx001. No abstract available.

8.

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, van Velkinburgh J, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jager W, Price DK, Chau CH, Figg WD.

Mol Cancer Res. 2017 Aug;15(8):1096-1105. doi: 10.1158/1541-7786.MCR-16-0477. Epub 2017 Apr 7.

9.

Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer.

Feinman HE, Price DK, Figg WD.

Cancer Biol Ther. 2017 Apr 3;18(4):203-204. doi: 10.1080/15384047.2017.1295192. Epub 2017 Feb 25.

10.

Deciphering the Routes of invasion of Drosophila suzukii by Means of ABC Random Forest.

Fraimout A, Debat V, Fellous S, Hufbauer RA, Foucaud J, Pudlo P, Marin JM, Price DK, Cattel J, Chen X, Deprá M, François Duyck P, Guedot C, Kenis M, Kimura MT, Loeb G, Loiseau A, Martinez-Sañudo I, Pascual M, Polihronakis Richmond M, Shearer P, Singh N, Tamura K, Xuéreb A, Zhang J, Estoup A.

Mol Biol Evol. 2017 Apr 1;34(4):980-996. doi: 10.1093/molbev/msx050.

11.

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.

Sissung TM, Deeken J, Leibrand CR, Price DK, Ehrlich S, Steinberg SM, Liewehr DJ, Dahut W, Figg WD.

Pharmacogenomics. 2016 Dec;17(18):1979-1986. Epub 2016 Nov 24.

12.

Androgen receptor variation affects prostate cancer progression and drug resistance.

McCrea E, Sissung TM, Price DK, Chau CH, Figg WD.

Pharmacol Res. 2016 Dec;114:152-162. doi: 10.1016/j.phrs.2016.10.001. Epub 2016 Oct 7. Review.

13.

Genetic analysis of an ephemeral intraspecific hybrid zone in the hypervariable tree, Metrosideros polymorpha, on Hawai'i Island.

Stacy EA, Johansen JB, Sakishima T, Price DK.

Heredity (Edinb). 2016 Sep;117(3):173-83. doi: 10.1038/hdy.2016.40. Epub 2016 Jun 15.

14.

Hybrid sterility and evolution in Hawaiian Drosophila: differential gene and allele-specific expression analysis of backcross males.

Brill E, Kang L, Michalak K, Michalak P, Price DK.

Heredity (Edinb). 2016 Aug;117(2):100-8. doi: 10.1038/hdy.2016.31. Epub 2016 May 25.

15.

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.

Schmidt KT, Chau CH, Price DK, Figg WD.

J Clin Pharmacol. 2016 Dec;56(12):1484-1499. doi: 10.1002/jcph.765. Epub 2016 Jun 17. Review.

16.

Genomic Signatures of Speciation in Sympatric and Allopatric Hawaiian Picture-Winged Drosophila.

Kang L, Settlage R, McMahon W, Michalak K, Tae H, Garner HR, Stacy EA, Price DK, Michalak P.

Genome Biol Evol. 2016 May 30;8(5):1482-8. doi: 10.1093/gbe/evw095.

17.

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD.

Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10.

18.

YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?

Kyritsi F, Price DK, Figg WD.

Cancer Biol Ther. 2016 Jun 2;17(6):592-4. doi: 10.1080/15384047.2016.1178883. Epub 2016 May 5.

19.

Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?

Leibrand CR, Price DK, Figg WD.

Cancer Biol Ther. 2016 May 3;17(5):467-9. doi: 10.1080/15384047.2016.1156274. Epub 2016 Mar 17.

20.

Building a hit list for the fight against metastatic castration resistant prostate cancer.

Strope JD, Price DK, Figg WD.

Cancer Biol Ther. 2016;17(3):231-2. doi: 10.1080/15384047.2016.1139270. Epub 2016 Jan 29.

21.

New bigenic mouse model increases the understanding of genetic synergism in the progression of prostate cancer.

Polman DJ, Price DK, Figg WD.

Cancer Biol Ther. 2015;16(12):1702-3. doi: 10.1080/15384047.2015.1108498.

22.

Postzygotic barriers isolate sympatric species of Cyrtandra (Gesneriaceae) in Hawaiian montane forest understories.

Johnson MA, Price DK, Price JP, Stacy EA.

Am J Bot. 2015 Nov;102(11):1870-82. doi: 10.3732/ajb.1500288. Epub 2015 Nov 5.

23.

Rapid adaptive radiation and host plant conservation in the Hawaiian picture wing Drosophila (Diptera: Drosophilidae).

Magnacca KN, Price DK.

Mol Phylogenet Evol. 2015 Nov;92:226-42. doi: 10.1016/j.ympev.2015.06.014. Epub 2015 Jul 4.

PMID:
26151218
24.

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD.

PLoS One. 2015 May 8;10(5):e0126672. doi: 10.1371/journal.pone.0126672. eCollection 2015.

25.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.

26.

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.

Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Ambrosone CB, Thompson IM.

Urology. 2015 Mar;85(3):616-20. doi: 10.1016/j.urology.2014.11.024.

27.

Physiological effects of heat stress on Hawaiian picture-wing Drosophila: genome-wide expression patterns and stress-related traits.

Uy KL, LeDuc R, Ganote C, Price DK.

Conserv Physiol. 2015 Feb 18;3(1):cou062. doi: 10.1093/conphys/cou062. eCollection 2015.

28.

BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.

Lochrin SE, Price DK, Figg WD.

Cancer Biol Ther. 2014;15(12):1583-5. doi: 10.4161/15384047.2014.962297. Review.

29.

Genetic variation: effect on prostate cancer.

Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R.

Biochim Biophys Acta. 2014 Dec;1846(2):446-56. doi: 10.1016/j.bbcan.2014.08.007. Epub 2014 Sep 6. Review.

30.

Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation.

Srivastava A, Price DK, Figg WD.

Cancer Biol Ther. 2014 Oct;15(10):1293-5. doi: 10.4161/cbt.29694. Epub 2014 Jul 9.

31.

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JK, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS.

Urology. 2014 Jul;84(1):127-31. doi: 10.1016/j.urology.2014.03.015. Epub 2014 May 10.

32.

Incipient radiation within the dominant Hawaiian tree Metrosideros polymorpha.

Stacy EA, Johansen JB, Sakishima T, Price DK, Pillon Y.

Heredity (Edinb). 2014 Oct;113(4):334-42. doi: 10.1038/hdy.2014.47. Epub 2014 May 14.

33.

Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2.

Burckart GJ, Figg WD 2nd, Brooks MM, Green DJ, Troutman SM, Ferrell R, Chinnock R, Canter C, Addonizio L, Bernstein D, Kirklin JK, Naftel D, Price DK, Sissung TM, Girnita DM, Zeevi A, Webber SA.

J Pediatr Pharmacol Ther. 2014 Jan;19(1):16-24. doi: 10.5863/1551-6776-19.1.16.

34.

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.

Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD.

Mol Cancer. 2014 Apr 28;13:91. doi: 10.1186/1476-4598-13-91.

35.

The androgen receptor transcriptional program in castration-resistant prostate cancer: cell lines vs. tissue samples.

Roth JE, Peer CJ, Price DK, Figg WD.

Cancer Biol Ther. 2014 Jan;15(1):16-8. doi: 10.4161/cbt.27149. Epub 2013 Nov 19.

36.

Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease.

Fernández EV, Price DK, Figg WD.

Cancer Biol Ther. 2013 Nov;14(11):1005-6. doi: 10.4161/cbt.26339. Epub 2013 Sep 4.

37.

Theriogenology question of the month. Granulosa cell tumor diagnosis.

Vanderwall DK, Price DK, Stott RD, Baldwin TJ.

J Am Vet Med Assoc. 2013 Sep 15;243(6):791-3. doi: 10.2460/javma.243.6.791. No abstract available.

PMID:
24004224
38.

Gene discordance in phylogenomics of recent plant radiations, an example from Hawaiian Cyrtandra (Gesneriaceae).

Pillon Y, Johansen JB, Sakishima T, Roalson EH, Price DK, Stacy EA.

Mol Phylogenet Evol. 2013 Oct;69(1):293-8. doi: 10.1016/j.ympev.2013.05.003. Epub 2013 May 15.

PMID:
23685062
39.

Patterns and processes in complex landscapes: testing alternative biogeographical hypotheses through integrated analysis of phylogeography and community ecology in Hawai'i.

Eldon J, Price JP, Magnacca K, Price DK.

Mol Ecol. 2013 Jul;22(13):3613-28. doi: 10.1111/mec.12326. Epub 2013 May 17.

PMID:
23683316
40.

Potential use of low-copy nuclear genes in DNA barcoding: a comparison with plastid genes in two Hawaiian plant radiations.

Pillon Y, Johansen J, Sakishima T, Chamala S, Barbazuk WB, Roalson EH, Price DK, Stacy EA.

BMC Evol Biol. 2013 Feb 9;13:35. doi: 10.1186/1471-2148-13-35.

41.

Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?

Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, Spencer SD, Price DK, Figg WD.

BMJ Open. 2013 Jan 3;3(1). pii: e002030. doi: 10.1136/bmjopen-2012-002030.

42.
43.

Bcl-2 family of proteins as therapeutic targets in genitourinary neoplasms.

Hall C, Troutman SM, Price DK, Figg WD, Kang MH.

Clin Genitourin Cancer. 2013 Mar;11(1):10-9. doi: 10.1016/j.clgc.2012.09.002. Epub 2012 Oct 17. Review.

PMID:
23083798
44.

Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.

Oncologist. 2012;17(3):312-20. doi: 10.1634/theoncologist.2011-0315. Epub 2012 Mar 1.

45.

Significant addition to treatment options for bone metastasis in prostate cancer.

Richardson ED, Price DK, Figg WD.

Cancer Biol Ther. 2012 Jan 15;13(2):69-70. doi: 10.4161/cbt.13.2.18441.

46.

SLCO transport genes in prostate cancer--letter.

Sissung TM, Pressler H, Price DK, Figg WD.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2325; author reply 2326-7. doi: 10.1158/1055-9965.EPI-11-0606. Epub 2011 Sep 6. No abstract available.

47.

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.

Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.

Cancer Causes Control. 2011 Aug;22(8):1121-31. doi: 10.1007/s10552-011-9787-7. Epub 2011 Jun 11.

48.

Expression of OATP family members in hormone-related cancers: potential markers of progression.

Pressler H, Sissung TM, Venzon D, Price DK, Figg WD.

PLoS One. 2011;6(5):e20372. doi: 10.1371/journal.pone.0020372. Epub 2011 May 19.

49.

The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.

Gao R, Reece K, Sissung T, Reed E, Price DK, Figg WD.

Mutat Res. 2011 Mar 15;708(1-2):21-7. doi: 10.1016/j.mrfmmm.2011.01.002. Epub 2011 Feb 16.

50.

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.

English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD.

Ther Clin Risk Manag. 2010 Nov 19;6:579-83. doi: 10.2147/TCRM.S14303.

Supplemental Content

Loading ...
Support Center